Latest news with #QIS
Time of India
01-08-2025
- Business
- Time of India
QIS signs MoU with Quantum Research and Centre of Excellence (QRACE); to boost quantum tech research & innovation
VIJAYAWADA: Fa mou s engineering colleges group from AP-QIS educational institutions, Ongole, has signed a strategic Memorandum of Understanding (MoU) with Quantum Research and Centre of Excellence (QRACE), New Delhi, marking a monumental step towards advancing India's quantum innovation ecosystem. This alliance paves the way for robust collaboration in quantum computing, post-quantum cryptography, quantum sensing, quantum communication, and AI integration, fostering innovation that addresses global challenges in healthcare, transportation, defense, and cybersecurity. The partnership will witness joint R&D initiatives, establishment of Centres of Excellence (CoEs), co-development of advanced quantum devices, and paid internships for QIS students at QRACE. The MoU also facilitates joint supervision of PhD scholars, access to advanced infrastructure, and joint funding proposals under national missions like the National Quantum Mission (NQM), DRDO, DST, and Defence. QIS chairman Prof. Dr. N S Kalyan Chakravarthy said the collaboration with QRACE reflects QIS's unwavering commitment to cutting-edge research and global partnerships in emerging technologies. 'I congratulate our faculty and leadership team for steering QIS to the forefront of quantum innovation. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas Prices In Dubai Might Be More Affordable Than You Think Villas In Dubai | Search Ads Get Quote Undo Together with QRACE, we will groom the next generation of quantum scientists and innovators for the nation,' said Dr Chakravarthy. The MoU was signed by Dr. Kumar Gautam, founder and president of QRACE, and Dr. N S Kalyan Chakravarthy, executive chairman of QIS Educational Institutions, in the presence of Prof. Dr. S Jafar Ali Ibrahim, member–governing council, QIS. This partnership sets the stage for transformative innovations that will shape India's trajectory in the global quantum technology race. Speaking on the collaboration, Dr. Gayathri Devi vice, chairman of QIS educational institutions, extended her heartfelt wishes to the entire academic and research team. She said: 'This is not just a partnership. It's a vision stitched with purpose, science, and national pride.'
Time of India
30-07-2025
- Automotive
- Time of India
SUN Mobility raises $135 mn to introduce Africa's largest battery swapping network
SUN Mobility , a Bengaluru-based electric mobility solutions provider, has raised approximately $135 million over the past year to expand its battery swapping operations in India and establish Africa's largest network of battery swapping stations. The latest investment, led by Helios Climate and the Private Infrastructure Development Group (PIDG) will support e-mobility supply chain development in Africa and South-East Asia. Founded in 2017 by the SUN Group and Maini Group, SUN Mobility operates over 900 battery swapping stations globally and powers more than 50,000 electric vehicles across multiple segments. 'Our modular, fast, and scalable battery swapping ecosystem adapts to real-world mobility needs,' said Chetan Maini, Co-Founder and Chairman, SUN Mobility. 'With increasing demand for clean mobility in Africa, this investment enables us to extend our proven model to a new, high-potential region.' A boost to Africa's urbanisation Africa's rising urbanisation and reliance on two- and three-wheelers make it a key candidate for electric mobility transformation. The sector currently contributes about 5 per cent of the continent's CO₂ emissions and is expected to reach annual sales of 1.9 million vehicles by 2030. SUN Mobility's investor base includes Indian Oil Corporation Ltd (IOCL), Bosch, and Vitol — the parent company of Vivo Energy, Africa's largest fuel retailer. Tavraj Banga, Partner and Co-Head at Helios Climate, said 'With strong decarbonisation and economic benefits, it's ideally suited for Africa. We are proud to support their entry and help enable climate-resilient mobility solutions." The new capital will also fund the deployment of Quick Interchange Stations (QIS) and local battery manufacturing capabilities, aimed at reducing emissions and supporting government and fleet decarbonisation targets.
Time of India
30-06-2025
- Automotive
- Time of India
Indofast Energy and Motovolt Mobility join forces to foster e2W adoption
Indofast Energy , a 50:50 joint venture between Indian Oil Corporation and SUN Mobility, has announced a strategic partnership with e-mobility startup Motovolt Mobility to accelerate electric two-wheeler adoption in India. The alliance integrates Indofast's nationwide QIS battery-swapping infrastructure with Motovolt's newly launched MVS7, India's first multi-utility electric scooter. The partnership aims to tackle key EV adoption barriers—range anxiety, high battery costs, and limited charging infrastructure —through a Battery-as-a-Service (BaaS) model. This approach decouples battery ownership from the vehicle, significantly reducing upfront costs and offering a flexible, pay-per-use solution for commuters and businesses. 'This isn't just a partnership; it's a paradigm shift in Indian e-mobility,' said Rajat Malhan, Senior Vice President, Indofast Energy. 'We are eliminating the biggest hurdles to EV adoption, ensuring uninterrupted journeys and greater economic opportunities for users.' The MVS7 is engineered for both personal mobility and last-mile delivery. With a 2.5kW BLDC motor, 120 Nm torque, and a top speed of 50 km/h, it offers a range of up to 85 km per charge. Motovolt CEO Tushar Choudhary emphasised, 'This collaboration is a major step toward green mobility . The MVS7 combines high utility with affordability, and our partnership with Indofast ensures access to an expanding swapping ecosystem.' The partnership also includes a lifetime battery warranty, enhancing trust and long-term value.
Yahoo
29-04-2025
- Business
- Yahoo
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®
BURNABY, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Telix ARTMS, Inc. (ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug master file (DMF)1 for gallium-68 production using its QUANTM Irradiation System® (QIS®) cyclotron technology has been referenced for the first time with a United States (U.S.) Food and Drug Administration (FDA) approved product, with Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection). This approval will enable radiopharmacies and hospitals using ARTMS' QIS® cyclotron technology and associated targets to produce multi-Curies of 68Ga for use with Gozellix®. The expanded distribution radius and increased dose production capacity, compared to existing gallium-based PET tracers, will facilitate broader and more equitable access. In addition, use of ARTMS' technology is being expanded internationally where regulatory submissions are in preparation. Pharmaceutical companies will be able to reference ARTMS' standardized isotope production technology with their approved drugs, helping to localize and simplify manufacturing. Chad Watkins, General Manager ARTMS and Isotope Strategy, Telix, said, 'This DMF reference represents a significant milestone for ARTMS, our partners and customers. The combination of these innovative technologies reflects Telix's commitment to working in partnership to reach more patients with 68Ga-PSMA-11, where and when they need it.' The QIS® forms part of ARTMS' 'turnkey' solution for customers that encompasses in-house manufactured targets and chemistry processing of isotopes, as well as DMF preparation and filing support. This makes large scale isotope production for hospitals and radiopharmaceutical distributors with cyclotrons significantly more attainable than with other existing technologies. ARTMS will continue to support the high efficiency, large-scale and cost-effective production of commercially important medical isotopes such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu), and will continue to partner with additional radiopharmaceutical companies to ensure that these critical isotopes are available on demand for patients. In addition, ARTMS' portfolio of advanced cyclotron technologies has application for Telix and select partners in the production of future commercially important alpha-emitting, therapeutic isotopes, including actinium-225 (225Ac) and astatine-211 (211At). For further information please contact: Chad Watkins Telix Pharmaceuticals LimitedGeneral Manager of ARTMS & Isotope StrategyEmail: Kevin ReimerTelix ARTMS, Global Sales and MarketingEmail: About Telix ARTMS, Inc. Based in Burnaby, British Columbia, Canada, Telix ARTMS, Inc. (ARTMS) is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world's most-used diagnostic imaging isotopes. ARTMS' flagship product, the QUANTM Irradiation System® (QIS®), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS was acquired by Telix Pharmaceuticals in April 20242. For more information on QIS® and ARTMS, please follow us on X @ARTMS_TLX and LinkedIn and visit About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA3. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: Legal Notices You should read this announcement together with Telix risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. _______________________ 1 A DMF is a submission to FDA used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products.2 Telix ASX disclosure 11 April 2024.3 Telix ASX disclosure 21 March in to access your portfolio
Yahoo
06-04-2025
- Business
- Yahoo
Telix Appoints Paul Schaffer as Chief Technology Officer
MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today. Dr. Schaffer has been CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024) for the past seven years, as well as Director, Life Science at TRIUMF, Canada's particle accelerator research centre, since 2012. Based in Vancouver, Canada, Dr. Schaffer is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotron radiochemistry facility and the development of the ARTMS QUANTM Irradiation System® (QIS®) for large-scale isotope production, which was commercialized and later acquired by Telix. As Telix CTO, Dr. Schaffer will be responsible for harnessing the power of technology to advance Telix's capabilities in radiopharmaceutical research, development, and clinical applications. Dr. Schaffer will cover areas including chemistry, physics, artificial intelligence (AI), dosimetry, and data analytics, complementing the work of Telix's Chief Scientist, Dr. Michael Wheatcroft, and his team in driving cutting-edge research and development (R&D). Dr. Schaffer said, "I'm excited to be taking on this role at such a pivotal time for Telix, as the Company advances rapidly toward its mission of transforming patient care. Telix has a bold commitment to innovation, and I'm thrilled to collaborate with this talented team to help drive R&D for the technologies behind the next generation of radiotherapeutics." Dr. Christian Behrenbruch, Telix Managing Director and Group Chief Executive Office, said, "Paul has an impressive track record of driving innovation in life sciences technology, including his groundbreaking work in large-scale isotope production. I have first-hand experience of Paul's impressive intellect, ideas and passion through his work at TRIUMF and with ARTMS, so it is a great pleasure to have him join the broader Telix team as we continue to lead radiopharmaceutical innovation." About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor RelationsMs. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. View original content to download multimedia: SOURCE Telix Pharmaceuticals Limited Sign in to access your portfolio
